[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577828":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":12,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":12,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":12,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":12,"overallStatus":41,"whyStopped":12,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Beijing Municipal Administration of Hospitals","OTHER_GOV",[8,13,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A:baseline anti-HBs titer≥100 mIU\u002Fml","NO_INTERVENTION","Patients with anti-HBs titer ≥100 mIU\u002Fml at baseline were selected as group A",null,{"label":14,"type":10,"description":15,"interventionNames":12},"Group B:baseline anti-HBs titer\u003C100 mIU\u002Fml","Patients with anti-HBs titer\\\u003C100 mIU\u002Fml at baseline were randomly divided into group B and group C, and group B did not receive intervention",{"label":17,"type":18,"description":19,"interventionNames":20},"Group C:baseline anti-HBs titer\u003C100 mIU\u002Fml","EXPERIMENTAL","Patients with anti-HBs titer\\\u003C100 mIU\u002Fml at baseline were randomly divided into group B and group C, and group C received hepatitis B vaccine injection.",[21],"Biological: baseline anti-HBs titer",[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":12},"BIOLOGICAL","baseline anti-HBs titer","Patients with baseline anti-HBs titer\\\u003C100 mIU\u002Fml were randomly divided into two groups, group B and group C. Group B did not intervene, while group C received hepatitis B vaccine intervention and observed its indicators.",[17],[29],{"name":30,"affiliation":31,"role":32},"Minghui Li","Beijing Ditan Hospital","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":12,"email":38},"Lu Zhang","CONTACT","13581975577","zhanglu1218@126.com",[40],{"facility":31,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","Beijing Municipality","100015","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":35,"role":36,"phone":37,"phoneExt":12,"email":38},{"type":32,"investigatorFullName":30,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Head of Department","100577828","research-on-clinical-recovery-and-maintenance-strategies-for-chb-100577828",false,"NCT06803368","Research on Clinical Recovery and Maintenance Strategies for CHB","Research on Clinical Recovery and Maintenance Strategies for Chronic Hepatitis B","Inclusion Criteria:\n\n* Age between 18 and 65 years old;\n* Gender is not limited;\n* CHB patients who meet the diagnostic criteria of the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B \\[5\\];\n* Confirmed interferon treatment resulted in HBsAg disappearance, HBeAg negativity, and HBV DNA below the lower detection limit and cessation Patients treated with interferon;\n* Sign a written informed consent form.\n\nExclusion Criteria:\n\n* Merge with other hepatitis virus (HCV, HDV) infections;\n* Autoimmune liver disease;\n* HIV infection;\n* Long term alcohol abuse and\u002For other liver damaging drugs;\n* Mental illness;\n* Evidence of liver tumors (liver cancer or AFP\\>100ng\u002Fml);\n* Decompensated cirrhosis;\n* Individuals with serious diseases of the heart, brain, lungs, kidneys, and other systems who cannot participate in long-term follow-up.","ALL","18 Years","65 Years",{"count":68,"type":69},285,"ESTIMATED","INTERVENTIONAL",[72],"NA","Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti HBe, HBcrAg, anti HBc), AFP, Fibroscan, liver imaging examinations will be conducted every 3-6 months, and blood samples will be retained for monitoring the frequency of immune cells (pDC, Treg) and the expression of functional molecules, as well as cytokines (IFN - γ, IP-10, IL-10, and TGF - β). Observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.",[75,76],"Chronic Hepatitis b","Hepatitis B Vaccine","2025-01-26",{"date":79,"type":80},"2025-01-31","ACTUAL",{"date":82,"type":80},"2024-11-01",{"date":84,"type":69},"2027-10-30",{"name":5,"class":6},1]